Business
Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference
Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference Halle (Saale) / Munich, Germany, April 9, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following investor conference: Van Lanschot Kempen Life Sciences ConferenceDate: April 16, 20
About this update from Vivoryon Therapeutics N.v.
[{"type":"image","alt":"Vivoryon Therapeutics N.V.","displaySize":"","headline":null,"caption":"Vivoryon Therapeutics N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/svDzxvBEhKQKFGa9AT1tMA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNA--/https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c","width":300,"height":96}},"lazy":false},{"type":"text","content":"Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference","length":65,"tagName":"p"},{"type":"text","content":"Halle (Saale) / Munich, Germany, April 9, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following investor conference:","length":371,"tagName":"p"},{"type":"text","content":"Van Lanschot Kempen Life Sciences ConferenceDate: April 16, 2026Location: Amsterdam, The NetherlandsAttendee: Julia Neugebauer, PhD, COO","length":139,"tagName":"p"},{"type":"text","content":"###","length":3,"tagName":"p"},{"type":"text","content":"About Vivoryon Therapeutics N.V.","length":32,"tagName":"p"},{"type":"text","content":"Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com","length":615,"tagName":"p"},{"type":"text","content":"Vivoryon Forward Looking StatementsThis press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projec...